



# PATHFAST™ D-Dimer

## <REAGENT FOR PATHFAST>

60 Tests

English

### Intended use

PATHFAST D-Dimer is a product for in-vitro diagnostic use with the in vitro diagnostic (IVD) automated analyser PATHFAST for the quantitative measurement of D-dimer in whole blood or plasma. PATHFAST D-Dimer is intended to be used:

- as an aid in the diagnosis of activation processes of the coagulation system including deep vein thrombosis (DVT) and pulmonary embolism (PE),
  - by laboratory technician, nurse or physician,
  - in hospital including emergency room, doctor's office and clinical laboratory.
- PATHFAST D-Dimer is a device for near patient testing (NPT).

### Summary

Plasmin-induced lysis of cross-linked fibrin results in the formation of D-dimer containing fibrin degradation fragments (XDP). D-dimer is a specific marker of the degradation of factor XIIIa- crosslinked fibrin and an indirect early marker of activation of coagulation and clot formation. The plasma concentration of D-dimer is elevated in clinical conditions associated with activation processes of the coagulation system including DVT, PE, and disseminated intravascular coagulation (DIC) (1-4). The exclusion of DVT or PE in patients suspected of venous thromboembolism is possible if the D-dimer concentration is below the cut off value established by numerous clinical studies (5-12).

### Test principle

The PATHFAST D-Dimer procedure is based on chemiluminescent enzyme immunoassay (CLEIA) and MAGTRATION. All required components for performing the testing are packed in one reagent cartridge. By loading PATHFAST D-Dimer into the in vitro diagnostic system PATHFAST, D-dimer can be accurately quantified within 17 min. In this procedure, alkaline phosphatase labelled anti-D-dimer monoclonal antibody (MoAb) and anti-D-dimer MoAb coated magnetic particles are mixed with the sample. D-dimer contained in the specimen binds to the anti-D-dimer antibodies forming an immunocomplex with enzyme labelled antibody and antibody coated magnetic particles. After removing the unbound enzyme labelled antibody, a chemiluminescent substrate is added to the immunocomplex. After a short incubation, the luminescence generated by enzyme reaction is detected. The D-dimer concentration in the specimen is calculated by means of a standard curve.

\*"MAGTRATION" is technology of B/F separation where magnetic particles are washed in a pipette tip and is a trademark or registered trademark of Precision System Science Co., Ltd.

### Package composition of materials provided

Reagent cartridge 6 cartridges x 10 trays

The reagent cartridge consists of 16 wells. All wells with the exclusion of the sample well (# 1) and counting well (# 10) are covered with an aluminium seal having a bar code. All reagents for the test are filled in each well of the reagent cartridge. Do not reuse a reagent cartridge. This is designed for single use only.

Wells	Form	Ingredient	Quantity	Source
# 1	Empty	Sample well	-	-
# 2	Liquid	Alkaline phosphatase conjugated anti-D-dimer MoAb, Na azide (< 0.1%)	50 µL	Calf intestine Mouse
# 7	Liquid	anti-D-dimer MoAb coated magnetic particles	50 µL	Mouse
# 13	Liquid	Chemiluminescent substrate, CDP-Star	100 µL	-
# 11	Liquid	Sample dilution buffer Na azide (< 0.1%), Triton X-100 (< 0.1%)	50 µL	-
# 3, 4, 5	Liquid	Washing buffer Na azide (< 0.1%), Triton X-100 (< 0.1%)	400 µL	-
# 1, 6, 8, 9, 10, 12, 14, 15, 16 are empty wells. "CDP-Star" is a trademark or registered trademark of Applied Biosystems, LLC.				

Calibrator 1 (CAL-1)	2.0 mL x 1 bottle (liquid, Na azide < 0.1%)
Calibrator 2 (CAL-2)	For 1.0 mL x 2 vials (lyophilized)
Calibrator diluent	1.0 mL x 2 bottles (liquid, Na azide < 0.1%)
MC ENTRY CARD	1 sheet
Instruction for use	1 sheet

### Materials required but not provided

PATHFAST Analyser (Product #: 300929) and consumables  
PATHFAST TIP (Product #: 300936)  
PATHFAST WASTE BOX (Product #: 300950)  
D-dimer Quality Control Materials  
PATHFAST SAMPLE DILUENT 3 (Product #: PF03D)

### Precautions and warnings

- Do not peel off the aluminium seal of the reagent cartridge.
- Handle the reagent cartridge by holding the edge of it and do not touch the aluminium seal or the black well with your fingers.
- When the reagent cartridge is dropped and damaged, do not use it.
- Avoid contamination of saliva in the black well.
- Avoid contamination of foreign substances such as fungi, bacteria and detergent into the specimen.
- After a certain period of storage or shipment, there may be some reagents adhered to the aluminium seal. If such a condition is observed, gently tap the cartridge on the table before use.
- Store the reagent cartridges in an upright position at all times.
- CAL-2 contains human serum. Although the used raw materials were negative for HBs antigen, HIV antibody and HCV antibody, it should be handled as infectious due to a risk of infections.
- Used reagent cartridges contain bodily fluids. Handle with appropriate care to avoid skin contact and injection.
- Azide can react with copper and lead used in some plumbing systems to form explosive salts. When disposing of azide-containing materials, they should be flushed away with large volumes of water.
- Dispose of all measured reagents and materials according to the standard disposal method. For example, autoclave at 121 °C for 20 minutes. Follow general precautions and handle all components as if capable of transmitting infectious agents.
- The PATHFAST reporting system contains error codes to warn the operator of specific malfunctions. Any reports containing such error codes should be held for follow-up. See the PATHFAST operator's manual.
- Patient samples may contain heterophilic antibodies that could react in immunoassay to give a falsely high or low result. This assay has been designed to minimize interference from heterophilic antibodies. Nevertheless, complete elimination of this interference from all patient specimens cannot be guaranteed. A test result that is inconsistent with the clinical picture and patient history should be interpreted with caution.
- The results should be evaluated in context of all laboratory findings and the total clinical status of the patient. In cases where the laboratory results do not match the clinical picture or history, additional tests should be performed.
- When any serious incident occurs in relation to the product, report to the manufacturer and the competent authority in which the user and/or the patient is located.

### Storage and expiration

- Store at 2 - 8 °C.
- Store the cartridge tray with the label side up.
- Avoid water damage during storage.
- Do not open the cartridge tray until just before use.
- Avoid contamination and exposure to direct sunlight.
- CAL-1 can be used until the expiration date after opening.
- CAL-2 is stable for 7 days at 2 - 8 °C and 3 months at -20 °C or lower after reconstitution.
- The expiration date is listed on each reagent cartridge and kit box label.
- Do not use reagents beyond the indicated expiration date.

### Sample collection

Use whole blood or plasma collected with qualified collection tube containing Na-heparin, Li-heparin, EDTA or citrate.

### Sample stability

Whole blood sample must be stored at 2 to 25 °C and analysed within 4 hours after collection.

Heparinized and citrated plasma samples are stable under the conditions below:

- 2 to 25 °C: 24 hours
- 20 °C or lower: 2 months (freeze only once)

EDTA plasma samples are stable under the conditions below:

- 2 to 25 °C: 3 hours
- 20 °C or lower: 2 months (freeze only once)

**Sample volume:** 100 µL

### Preparation and procedure

Refer to the PATHFAST operator's manual for detailed information of the analyser operation.

### Reagent preparation

1. Reagent cartridge: Ready to use.
2. CAL-1: Ready to use. (Limited to use with reagent of the same lot.)
3. CAL-2: Transfer the whole volume of one bottle of calibrator diluent into one vial of CAL-2. Do not use different lots of calibrator diluent to dissolve CAL-2. Stand for 15 minutes at room temperature after the reconstitution. Mix gently and ensure that calibrator is completely dissolved. (Limited to use with reagent of the same lot.)

### Installation of master calibration curve

1. Installation of a master calibration curve is necessary when a new reagent lot is used.
2. Install the master calibration curve by reading the bar code on MC ENTRY CARD, which is enclosed in each package, with the hand-held bar code reader of PATHFAST.

### User calibration

1. User calibration is necessary when a new reagent lot is used after installation of the master calibration curve from MC ENTRY CARD.
2. User calibration is also necessary every 4 weeks after the first user calibration. (MC ENTRY CARD is not required.)
3. The calibrators, CAL-1 and CAL-2, must be tested both in duplicate. Therefore, 4 reagent cartridges, two for CAL-1 and two for CAL-2 are necessary for user calibration.
4. Place the reagent cartridges in the cartridge rack, and then dispense approximately 100 µL of CAL-1 and CAL-2 in sample wells to load onto PATHFAST.
5. Push the START button of PATHFAST and perform assay for the calibration.

### Quality Control assay (QC assay)

1. QC assay is indispensable for assuring validity of sample results. QC assay is performed after every calibration to check the calibration curves and to obtain data from QC samples for quality control. After each calibration, with each new shipment of previously calibrated test kit, or whenever the institution wishes to verify the performance of the system, analyse two levels of quality control material with known concentrations of D-dimer
2. Good laboratory practice recommends the use of appropriate quality controls. It is recommended to follow national, federal, and local guidelines for quality control. If controls do not perform as expected, do not use the test results. Repeat the test or call your authorized PATHFAST distributor for technical service.

### Sample assay

1. Place the reagent cartridge in the cartridge rack, then dispense approximately 100 µL of sample into a sample well of a cartridge.
2. Load the cartridge rack onto PATHFAST and push the START button of PATHFAST to perform sample assay.

### Note

1. When a whole blood sample is used, the whole blood contained in a blood collection tube should be mixed gently just before dispensing. (Do not use a vortex mixer.) After dispensing the whole blood sample and loading the cartridge on PATHFAST, the assay must be started immediately.
2. When fibrin threads or clots and other insoluble materials are present in the plasma sample, such material must be removed by centrifugation or filtration.
3. When samples are left for more than 5 minutes after dispensing into a sample well, a lower result will be obtained analysing whole blood because of blood sedimentation and a higher result will be obtained analysing plasma because of increasing D-dimer concentration by evaporation.
4. When a whole blood sample is used, input of an individual haematocrit value of the sample in PATHFAST is optional.
5. Samples with results above 5 µg/mL FEU should be diluted with sample diluent (Product # PF03D) and retested if a quantitative result is desired or alternatively, they can be reported as > 5.00 µg/mL FEU.

### Specific performance data

Representative performance data on the PATHFAST are given below.

### Metrological traceability

The PATHFAST D-Dimer calibrator consists of high molecular weight fraction of human cross-linked fibrin degradation products obtained by plasmin fibrinolysis.

### Precision (repeatability)

Precision was assessed with whole blood and plasma samples at each 3 concentration levels. The samples were tested in 20 consecutive replicates. The following results were obtained.

Whole blood	Mean (µg/mL FEU)	S.D. (µg/mL FEU)	C.V. (%)
Level-1	0.400	0.020	5.0
Level-2	0.759	0.028	3.7
Level-3	1.54	0.048	3.1

Plasma	Mean (µg/mL FEU)	S.D. (µg/mL FEU)	C.V. (%)
Level-1	0.426	0.018	4.2
Level-2	0.830	0.026	3.1
Level-3	1.65	0.066	4.0

### Precision (reproducibility)

Plasma samples at 3 concentration levels within the measurement range were assayed in duplicate in each run, 2 runs per day, for 20 days with 1 reagent lot on 1 instrument, for a total of 40 runs. The within-run and total coefficient of variations (C.V.) were calculated with standard deviations (S.D.) according to the CLSI EP5-A2 protocol. The following results were obtained.

Sample	Mean (µg/mL FEU)	Within-run precision		Total precision	
		S.D. (µg/mL FEU)	C.V. (%)	S.D. (µg/mL FEU)	C.V. (%)
Level-1	0.027	0.001	3.7	0.002	7.4
Level-2	0.245	0.008	3.3	0.014	5.7
Level-3	2.43	0.113	4.7	0.138	5.7

### Analytical sensitivity

Limit of detection (LoD): 0.001 µg/mL FEU

Limit of quantitation (LoQ): 0.003 µg/mL FEU (C.V. 10%)

### Linearity

D-dimer antigen was spiked into plasma at 4 concentration levels (0.217, 0.983, 2.44, 7.47 µg/mL FEU). The samples were serially diluted with 5 or 7-fold and assayed. The recovery rate against the theoretical value was within 93 - 110% up to 7.47 µg/mL FEU.

**Assay range:** 0.005 - 5 µg/mL FEU

The assay range was set from the results of LoQ and linearity.

### High dose hook effect

There was no high dose hook effect for the samples with their D-dimer values up to 803 µg/mL FEU of high molecular weight molecules (XDP-polymer) and 160 µg/mL FEU of low molecular weight molecules (XDP-monomer).

### Analytical specificity

#### Interference of endogenous substances

The following factors were found to have an effect of less than 10% on the assay at the concentrations indicated in parentheses.

Free bilirubin	(60 mg/dL)
Conjugated bilirubin	(60 mg/dL)
Lipemia	(3000 FTU)
Triglyceride	(1000 mg/dL)
Haemoglobin (haemolysis)	(500 mg/dL)
Rheumatoid Factor	(500 IU/mL)

#### Interference of exogenous substances

The following drugs which might be used in target patients were found to have an effect of less than 10% on the assay at the concentrations indicated in parentheses.

Acetaminophen	(20 mg/dL)	Digoxin	(5 ng/mL)
Acetylsalicylic acid	(0.3 ng/mL)	Dopamine	(65 mg/dL)
Allopurinol	(2.5 mg/dL)	Erythromycin	(20 mg/dL)
Ampicillin	(5 mg/dL)	Furosemide	(2 mg/dL)
Ascorbic acid	(3 mg/dL)	Methyldopa	(2.5 mg/dL)
Atenolol	(1 mg/dL)	Nifedipine	(6 mg/dL)
Caffeine	(10 mg/dL)	Phenytoin	(10 mg/dL)
Captopril	(5 mg/dL)	Theophylline	(25 mg/dL)
Verapamil	(16 mg/dL)		

**Cross-reactivity**

The following substances have no significant cross-reactivity on the assay at the concentration indicated in parentheses.

Fibrinogen	(5000 µg/mL)	Fragment X	(20 µg/mL)
Fragment Y	(20 µg/mL)	Fragment D	(20 µg/mL)

On the other hand, cross reactivity was observed with high concentration of fragment E (20 µg/mL). High concentration of E-fragments, such as found in patients receiving thrombolytic therapy, can lead to measurement of lower values.

**Correlation between Li-heparin or EDTA plasma samples and other sample matrices**

x	y		n	Slope	Intercept	r
Li-heparin plasma	Li-heparin	Whole blood	56	0.955	0.073	0.990
		Plasma	56	1.02	0.001	0.992
	Na-heparin	Whole blood	56	1.02	0.030	0.988
		Plasma	56	0.942	-0.015	0.991
EDTA plasma	EDTA	Whole blood	52	1.03	0.041	0.984
		Whole blood	52	1.01	-0.028	0.987

The regression equation was calculated by Passing-Bablok fit.

**Method comparison**

y= 1.10x + 0.053, r= 0.956, n= 211 (plasma samples, y: PATHFAST D-Dimer, x: Stratus CS DDMR TestPak, Passing-Bablok fit).

**Expected values**

The PATHFAST D-Dimer result is given in µg/mL FEU (fibrinogen equivalent unit).

- Using the PATHFAST D-Dimer assay, the preliminary reference interval measured in 186 healthy individuals was calculated to be: the upper 95<sup>th</sup> percentile value 0.666 µg/mL FEU. The measured D-dimer values ranged from 0.037 - 1.07 µg/mL FEU with a mean of 0.263 µg/mL FEU.
- The expected values/reference values may vary from laboratory to laboratory and from country to country depending on various factors. It is therefore recommended for each institution to establish corresponding expected values.
- A preliminary cut off value of 0.5 µg/mL FEU for exclusion of venous thromboembolism (PE or DVT) has been established using 60 plasma samples obtained from patients with PE independently diagnosed by echocardiography, spiral-CT and pulmonary angiography (12). For exclusion of DVT alone, several reports showed higher cut off values (0.57 µg/mL FEU or higher) (5, 8, 9). The sensitivity, specificity and NPV for PATHFAST D-Dimer using a cut off value of 0.570 µg/mL FEU were 100%, 63.2% and 100%, respectively (5).

**References**

- Weitz JI, Fredenburgh JC, Eikelboom JW. A Test in Context: D-Dimer. *J Am Coll Cardiol.* 2017 Nov 7;70(19):2411-2420.
- Johnson ED, Schell JC, Rodgers GM. The D-dimer assay. *Am J Hematol.* 2019 Jul;94(7):833-839.
- Halaby R, Popma CJ, Cohen A, et al. D-Dimer elevation and adverse outcomes. *J Thromb Thrombolysis.* 2015 Jan;39(1):55-9.
- Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. *Blood.* 2009 Mar 26;113(13):2878-87.
- Fukuda T, Kasai H, Kusano T, et al. A rapid and quantitative D-Dimer assay in whole blood and plasma on the point-of-care PATHFAST analyzer. *Thromb Res.* 2007;120(5):695-701.
- Gosselin RC, Wu JR, Kottke-Marchant K, et al. Evaluation of the Stratus CS Acute Care D-dimer assay (DDMR) using the Stratus CS STAT Fluorometric Analyzer: a prospective multisite study for exclusion of pulmonary embolism and deep vein thrombosis. *Thromb Res.* 2012 Nov;130(5):e274-8.
- Antovic JP, Höög Hammarström K, Forslund G, et al. Comparison of five point-of-care D-dimer assays with the standard laboratory method. *Int J Lab Hematol.* 2012 Oct;34(5):495-501.
- Oude Elferink RF, Loot AE, Van De Klashorst CG, et al. Clinical evaluation of eight different D-dimer tests for the exclusion of deep venous thrombosis in primary care patients. *Scand J Clin Lab Invest.* 2015 May;75(3):230-8.
- Geersing GJ, Toll DB, Janssen KJ, et al. Diagnostic accuracy and user-friendliness of 5 point-of-care D-dimer tests for the exclusion of deep vein thrombosis. *Clin Chem.* 2010 Nov;56(11):1758-66.
- Reber G, Bounameaux H, Perrier A, et al. A new rapid point-of-care D-dimer enzyme-linked immunosorbent assay (Stratus CS D-dimer) for the exclusion of venous thromboembolism. *Blood Coagul Fibrinolysis.* 2004 Jul;15(5):435-8.

- de Moerloose P, Palareti G, Aguilar C, et al. A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism. *Thromb Haemost.* 2008 Sep;100(3):505-12.
- Ivancic BT, Spanuth E, Giannitsis E. PATHFAST D-Dimer vs. VIDAS D-dimer Exclusion- a comparative evaluation in emergency patients with post hoc confirmed pulmonary embolism, Poster at 55<sup>th</sup> Annual meeting of the Society of Thrombosis and Haemostasis Research 16-19 Feb. 2011, Wiesbaden.

**Symbols**

LSI Medience Corporation uses the following symbols and signs in addition to those listed in the EN ISO 15223-1:2021 (Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements).



This symbol means "Device for near patient testing".  
(Symbols for self-testing and near-patient testing under the IVD Regulation 2017/746/EU. MedTech Europe. Dec. 13, 2018)



: Reagent cartridge



: Calibrator 1



: Calibrator 2



: Calibrator diluent



: Entry card for master calibration curve

\* PATHFAST: JP Registered Trademark No.5982733

Summary of safety and performance is available from:  
European Database on Medical Devices (EUDAMED).

Contact for technical assistance  
[www.pathfast.eu/contact](http://www.pathfast.eu/contact)



LSI Medience Corporation  
1-2-3 Shibaura, Minato-ku,  
Tokyo 105-0023, Japan



PHC Europe B.V.  
Nijverheidsweg 120, 4879 AZ, Etten-Leur,  
Netherlands